Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination by Chaccour, C.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118709
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
CASE STUDY Open Access
Ivermectin to reduce malaria transmission: a
research agenda for a promising new tool for
elimination
Carlos J Chaccour1,2*, Kevin C Kobylinski3, Quique Bassat4,5, Teun Bousema6,7, Chris Drakeley6, Pedro Alonso4,5
and Brian D Foy8*
Abstract
Background: The heterogeneity of malaria transmission makes widespread elimination a difficult goal to achieve.
Most of the current vector control measures insufficiently target outdoor transmission. Also, insecticide resistance
threatens to diminish the efficacy of the most prevalent measures, indoor residual spray and insecticide treated
nets. Innovative approaches are needed. The use of endectocides, such as ivermectin, could be an important new
addition to the toolbox of anti-malarial measures. Ivermectin effectively targets outdoor transmission, has a novel
mechanism of action that could circumvent resistance and might be distributed over the channels already in place
for the control of onchocerciasis and lymphatic filariasis.
Methods: The previous works involving ivermectin and Anopheles vectors are reviewed and summarized. A
review of ivermectin’s safety profile is also provided. Finally three definitive clinical trials are described in detail
and proposed as the evidence needed for implementation. Several smaller and specific supportive studies are
also proposed.
Conclusions: The use of ivermectin solves many challenges identified for future vector control strategies. It is
an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies
suggest it might become an effective and complementary strategy in malaria elimination and eradication
efforts; however, intensive research will be needed to make this a reality.
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Background
The last 15 years have seen renewed efforts towards con-
trolling malaria-associated morbidity and mortality, elimi-
nating malaria from endemic regions and even planning
eventual eradication. For these efforts, several research
agendas have been developed [1,2]. However, the gains in
malaria control over the last decade are severely threatened
by widespread insecticide resistance in vectors [3,4] and
emerging artemisinin-resistant Plasmodium falciparum
[5,6]. These threats pose a major challenge to the vision of
the Roll Back Malaria Partnership whereby malaria is no
longer a major cause of mortality by 2015 [7]. Global mal-
aria eradication will require new tools and the implementa-
tion of an integrated approach targeting the vector and
parasite in the ever changing human reservoir [1,8].
Vector control has traditionally been the mainstay of
malaria control in the past and is certain to remain so.
The Malaria Eradication (malERA) Consultative Group
on Vector Control has identified three main challenges
to developing vector-targeted interventions that support
elimination and eradication goals [9]. The first challenge
is developing a broader range of insecticides with novel
modes of action to counter current insecticide resistance
among Anopheles species [10]. Secondly, to develop con-
trol methods that affect outdoor feeding and resting vec-
tors; the current most effective tools, indoor residual
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spraying (IRS) and long-lasting insecticide-treated nets
(LLINs), do little to prevent outdoor transmission from
these vectors and can even drive exophagy and exophily
among them [11]. Lastly, new interventions are needed
to reduce the extremely high vectorial capacities of mal-
aria vectors in sub-Saharan Africa [12].
A potential new tool
Endectocides are drugs that have activity against endopara-
sites (mainly parasitic nematodes) and ectoparasites, (they
can kill arthropods that blood-feed on a treated subject).
Ivermectin is the only known endectocide currently ap-
proved for human use. It is a semi-synthetic derivate from
the fermentation products of Streptomyces avermectinius
[13]. Ivermectin primarily agonizes glutamate-gated chlo-
ride channels in invertebrates, causing flaccid paralysis and
death [13]. Glutamate-gated chloride channels do not exist
in humans and other weakly sensitive channels are found
in the human central nervous system, where the blood–
brain barrier limits drug access [14]. These characteristics
explain ivermectin’s excellent safety profile (see below).
Ivermectin is one of the few drugs used in human mass
drug administration (MDA) campaigns, and more than one
billion treatments have been delivered over the last 25 years
for controlling onchocerciasis and lymphatic filariasis [15].
Anopheles mosquitoes are particularly sensitive to
very low concentrations of ivermectin relative to other
vectors examined [16-18], thus offering promise for
malaria control. The methods used to examine ivermec-
tin’s effects on Anopheles have been diverse (Table 1),
including in vitro membrane feeding, direct blood feed-
ing on treated animals or humans [19,20], and wild
mosquito collections after they have fed on humans re-
ceiving ivermectin MDA [21-23]. These studies clearly
show that ivermectin is toxic to all Anopheles species
examined, and at concentrations found in human blood
after treatment.
Ivermectin addresses the three main challenges identi-
fied by the malERA vector control group [9]: (1) its mode
of action is different from the four currently used insecti-
cides for malaria vector control, thus it likely could cir-
cumvent the issue of emerging insecticide resistance; (2)
as a systemic drug, it is ingested by all biting mosquitoes
and so it will equally target indoor and outdoor-biting
mosquitoes, as well as those with crepuscular activity; and,
(3) the activity of the drug targets four out of the five
variables of vectorial capacity [33,34], especially the
most influential variable, the daily probability of mos-
quito survival. Ivermectin also fits many of the ideals
identified in the malERA initiative, including integra-
tion with the current vector control tools, any behav-
ioural adaptation away from biting treated humans
would only be beneficial, and it is expected to affect
vector population structure [35].
Ivermectin’s safety
The onchocerciasis control programme
The French authorities approved ivermectin for human
use in 1987. Soon after, Merck & Co Inc. decided to donate
ivermectin for onchocerciasis control and the MectizanW
Donation Program was created [13]. Since then, more
than a 1.5 billion treatments have been distributed in
Africa and Latin America for onchocerciasis control and
another 665 million for treatment of lymphatic filariasis
[15]. In this context, adverse events (AE) to ivermectin
have been usually mild, transient, associated with intensity
of microfilarial infection and primarily characterized as
mild Mazzoti-type reactions to dying microfilaria [36]. No
significant association has been found between ivermectin
plasma levels and AE [37].
Loa loa
The limited number of severe neurological AE seen with
ivermectin use, include encephalopathy and coma after
ivermectin administration to patients who were infected
with Loa loa. These reactions are closely related to the
microfilarial load and are due to parasite lysis rather than
drug toxicity [38]. Rapid assessment of loasis is now
recommended before ivermectin MDA in Loa-endemic
areas [39].
Higher or multiple doses
Several authors have evaluated the safety and tolerability
of ivermectin at doses different than those indicated.
Duke et al. [40] gave adult volunteers six fortnightly
doses of 100 μg/kg without observing severe AE. Awadzi
et al. [41] found no difference with controls in tolerance
and early AE using doses of up to 800 μg/kg. Guzzo
et al. [42] found no significant CNS toxicity or AE in
healthy volunteers taking either a single high dose of up to
2,000 μg/kg or repeated doses (three in a week) of up to
1,091 μg/kg. Kamgno et al. [43] randomized Onchocerca-
infected volunteers to different treatment schemes and
one group received 800 μg/kg every three months for
three years (accumulated dose of 8,950 μg/kg), but repor-
ted that all groups had comparable rates of AE. The high
dose group reported transitory mild and subjective visual
side effects more often (blurring of vision, changes in
colour vision, etc.), but ophthalmological examinations re-
vealed no structural explanation.
Children, pregnancy and lactation
Ivermectin is now licensed for the treatment of children
weighing more than 15 kg [44].
Pacque et al. [45] carried out a prospective study
in Liberia, where 14,000 people received the drug at
150 μg/kg. Out of some 4,000 women treated, 200 were
inadvertently treated during pregnancy. No significant
differences in birth defect rates, development status or
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Table 1 Studies evaluating Anopheles mosquito mortality and Plasmodium transmission after imbibing blood
containing ivermectin
Reference Methods Species Results
Pampiglione 1985
[24]
Feeding on impregnated cotton
and on treated mice.
An. stephensi Increased mortality in all groups feeding on impregnated
cotton, 100% mortality in those feeding at 28,000 μg/L.
Dose: 140–28,000 μg/kg
(once, subcutaneous)
100% mortality 24-hr post feeding on mice treated at dose
≥2,800 μg/kg. Increased mortality in all other dose-groups.
Iakubovich 1989
[25]
Membrane and feeding on treated rabbits.
Dose: 340 μg/kg (once, subcutaneous)
An. stephensi Death rates among An. stephensi fed on rabbits 4, 5 and
6 days after administration of the drug were 93, 70 and
79%, respectively.
An. atroparvus No difference with control seen in An. sacharovi and
An. atroparvus.An. sacharovi
Jones 1992 [26] Membrane and feeding on treated dogs
Dose: 10–2,500 μg/kg (once, orally)
An. quadrimaculatus Mortality ≥90% in all but one treatment groups 24-hr post
blood feeding and ≥90% in all groups 48-hr post blood feeding
Gardner 1993 [27] Feeding on treated dogs An. quadrimaculatus Significant increase in mortality. LD50 = 9.9 μg/kg [6.0, 13.8]
Dose: 6–24 μg/kg (once, orally) Significant decrease in oviposition and egg-hatching from
survivors
Bockarie 1999 [21] Field collections of engorged females
before and after MDA for lymphatic filariasis
An. punctulatus Significant decrease in 9-day cumulative survival rate of
Anopheles spp. collected 1–3 days post-treatment (0%)
vs those collected pre-treatment (67%)Dose: 400 μg/kg ivermectin +/− 6 mg/kg DEC
(once, orally) An. koliensis The 48-hr survival rate of An. puctulatus collected from two
houses in the a treated village the morning following MDA
was 31% vs 94% from two houses of an untreated village
Pre- and post-treatment all-night landing catches showed
no significant reduction in human biting rates.
Foley 2000 [20] Feeding on one treated human volunteer
Dose: 250 μg/kg (once, orally)
An. farauti 12-day cumulative mortality rate of mosquitoes was 100%,
95%, 93%, and 40% for those fed 0, 7, 10 and 14 days
post-treatment vs 10% for those fed pre-treatment
Fritz 2009 [28] Membrane and feeding on treated cattle An. gambiae Membrane feeding: LC50 for An. gambiae s.l. was 19.8 ± 2.8
ppb; no oviposition from mosquitoes fed on >10 ppbDose: 600 μg/kg (once, subcutaneously)
An. arabiensis Cattle feeding: Total cumulative survival of An. gambiae s.s.
significantly different from controls when fed up to 20 days
post-treatment; no or significantly reduced oviposition
when fed up to 17 days post-treatment
Chaccour 2010
[19]
Feeding on randomized, treated volunteers
and controls
Mean 12-day survival time of 2.38 days [1.52, 3.24] for
mosquitoes fed on treated subjects at 1 day post-treatment vs
5.52 days [4.65, 6.4] for mosquitoes fed on untreated control
subjects
Dose: 200 μg/kg (once, orally)
An. gambiae No effect on mosquitoes fed on treated subjects at 14 days
post-treatment
Kobylinski 2010
[16]
membrane feedings
Dose: NA
An. gambiae LC50 = 22.4 ng/ml [18.0, 26.9]. At sub-lethal concentrations,
significantly reduced mosquito re-blood feeding rates and
a second ivermectin blood meal, even at a decreased
concentration, further increased mortality
Sylla 2010 [23] Field collections of engorged females before
and after MDA for onchocerciasis
An. gambiae 5-day cumulative survival of An. gambiae s.s. was significantly
reduced from 3 treated villages vs pair-matched control villages
Dose: 150 μg/kg (once, orally) An. arabiensis An. gambiae s.s. captured in treated villages 1–6 days post-
treatment had significantly reduced survival v those caught
pre-MDA and those caught >7 days post-treatment
Kobylinski 2011
[22]
Field collections of engorged females
before and after MDA for onchocerciasis
An. gambiae For 12 days after the MDA, mean P. falciparum sporozoite rate
was significantly reduced by 79% in 3 replicate treated villages
while it increased by 246% in pair-matched control villagesDose: 150 μg/kg (once, orally)
Butters 2012 [29] Membrane feeding
Dose: NA
An. gambiae Sub-lethal concentrations (LC25 & LC5) caused significant
knockdown and reduced recovery rates
Fritz 2012 [30] Membrane feeding
Dose: NA
An. arabiensis LC50 = 7 · 9 ppb [6.2, 9.9]; oviposition among survivors
was significantly reduced at ≥7 ppb
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disease patterns could be found when comparing with un-
treated mothers in the same population. These findings
have been confirmed in hundreds of women in North
Cameroon [46], Mali [47], Ghana [48] and Uganda [49].
Thus, pregnant women in onchocerciasis-endemic areas
at high risk of loss of sight are no longer excluded from
ivermectin treatment [50].
Ivermectin levels in human breast milk are low. After
a single oral dose of 150 μg/kg in healthy women,
Ogbuokiri et al. [51] found peak levels of 14.13 +/− 0.43
ng/ml after 6.5 hours. Therefore, a breast-fed new born
would get a dose of only 2.75 μg/kg. It is no longer
recommended to exclude nursing women during MDA
of Mectizan in onchocerciasis-endemic areas [50].
Applying ivermectin for malaria control
As suggested in the publications in Table 1, and by pre-
vious modelling exercises [20,23,35] there are several
theoretical ways that ivermectin might be applied to help
control malaria:
1) In ongoing onchocerciasis and lymphatic filariasis
control campaigns, a single dose of ivermectin is
administered to entire villages on a single day during
MDA, with coverage rates generally between 60-80%.
This has positive collateral effects against soil-
transmitted helminthes, [52] and ectoparasites.
After MDA, most villagers’ blood is toxic to biting
Anopheles and this effect may last for approximately
six days [23]. These toxic blood meals can kill most
of the infectious adult mosquitoes, and while the
numbers of adult Anopheles feeding on people can
rebound quickly depending on the larval reservoir,
the new population is young and most have not
lived long enough to bite a gametocytaemic person
and become infectious (the minimum time required
for P. falciparum to develop in the vector is nine
days). Thus, sporozoite transmission can be
suppressed for weeks after MDA [22]. In this way,
ivermectin MDA might be ideal to stem malaria
epidemics, to interrupt brief transmission seasons
or offer sustained transmission reduction if given
repeatedly over longer transmission periods.
2) Recent publications have highlighted the likely
benefit of combining ivermectin with drugs such as
artemisinin combination therapy (ACT). ACT is
highly effective in most malaria-endemic settings but
does not prevent malaria-transmission in the first
weeks after treatment [53,54]. ACT in combination
with ivermectin may be an effective option for anti-
malarial MDA where residual transmission potential
is a major concern [55,56] and where mass
screening and treatment (MSAT) or drug
combinations fulfilling the single encounter radical
cure and prophylaxis (SERCaP) profile [57] are
alternative possibilities. Ivermectin would be an
additive, blocking onward transmission of parasites
from treated individuals by killing most Anopheles
biting the person and inhibiting Plasmodium
development in any surviving vectors. This would be
especially important to stem the spread of resistant
P. falciparum and a safe alternative for or in
addition to gametocytocidal drugs [58].
3) Treatment of peridomestic animals in areas where
Anopheles mosquitoes exhibit both zoophagic and
anthropophagic behaviour [30], not only with
ivermectin but with other classes of systemic
endectocides approved for veterinary use, is expected
to control the vector population size by increasing
mortality, reducing fertility and flying capacity and
may have further effects on transmission by inhibiting
sporogony in the surviving vectors.
Definitive studies
Before ivermectin can be recommended for malaria con-
trol, large-scale community trials must be conducted to
provide definitive evidence of its role in malaria control.
Below are what is envisioned as the three primary trials
required:
1) Single or repeated human ivermectin MDA for malaria
control
Design: placebo-controlled, cluster-randomized, double-
blind trial.
Table 1 Studies evaluating Anopheles mosquito mortality and Plasmodium transmission after imbibing blood
containing ivermectin (Continued)
Bastiaens 2012
[31]
Feeding on treated Swiss mice, Wistar
rats and Cynomolgus monkeys
Dose: 200–400 μg/kg
(different intervals, orally)
An. stephensi 3-day cumulative mortality of mosquitoes fed on treated
mice, rats and monkeys significantly differed from controls
when fed up to 2, 4 and 3 days post-treatment, respectively
Kobylinski 2012
[32]
Membrane feeding An. gambiae Sub-lethal concentrations significantly inhibited P. falciparum
sporogony when fed prior to, concurrent with, and 6 and
9 days after infection with gametocytes
Dose: NA
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Methods: single vs repeated ivermectin administration
to clusters (villages) over a non-continuous malaria
transmission season (e g, the rainy season) at the doses
and frequency determined by previous studies.
Entomological measures:
– Mosquito survival
– Mosquito population structure
– Mosquito immigration into clusters
– Entomological inoculation rate
– Vectorial capacity
Parasite measures:
– Sporozoite rates (mosquitoes)
– Plasmodium prevalence through periodic cross-
sectionals
– Molecular force of infection
– NTD and ectoparasite prevalence and intensity
Clinical measures:
– Malaria clinical disease incidence as detected by
passive case detection
– Serological markers of mosquito bite exposure [59,60]
– Anaemia prevalence
– Adverse events incidence
2) Comparison treatment of ivermectin vs ivermectin +
ACT
Design: individual-randomized, double-blind trial.
Methods: confirmed cases or asymptomatically infected
individuals are enrolled in ACT and ivermectin +ACT
arms. Doses and frequency determined by previous studies
Entomological measures:
– Colony mosquito survival and recovery after feeding
directly or indirectly on blood of treated subjects
Parasite measures:
– Sporogony assessment in fed mosquitoes
– Plasmodium clearance and rate
– Gametocyte carriage and infectiousness
Clinical measures:
– Safety and toxicology (blood chemistry,
haemoglobin, AEs)
– Malaria recovery rate and time to genetically
determined new infections after treatments
– PK/PD parameters of ivermectin and ACT
3) Livestock ivermectin/endectocide MDA for malaria
control in human population
Design: placebo-controlled, cluster-randomized, double-
blind trial.
Methods: repeated ivermectin/endectocide administra-
tion to the whole peridomestic livestock population liv-
ing around clusters. Doses and frequency determined by
previous studies
Entomological measures:
– Mosquito survival
– Mosquito population structure/size reduction
– Mosquito immigration into clusters
– Entomological inoculation rate
– Vectorial capacity
Parasite measures:
– Sporozoite rates (mosquitoes)
– Plasmodium prevalence/counts
– Molecular force of infection
– NTD and ectoparasite prevalence/intensity in both
animals and humans
Clinical measures:
– Malaria clinical disease incidence as detected by
passive case detection
– Anaemia prevalence
Supportive studies
Numerous studies are needed to fill knowledge gaps
about ivermectin’s effects on Anopheles, Plasmodium
and transmission. Some of these studies may be neces-
sary to complete before embarking in more specific clin-
ical trials, such as those proposed above.
Human plasma levels and mosquito mortality
Current estimates of LC50 of ivermectin for mosquitoes
are based on membrane feeding essays [16,28,32]. Simul-
taneous mosquito feeding and measurement of ivermectin
concentration in plasma (capillary and venous blood from
both men and women) can provide data for a correlation
and calculation of in vivo LC50 and time post-treatment
that the anti-mosquito/anti-sporogonic effect lasts. This
crucial information, combined with current knowledge of
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ivermectin’s pharmacokinetics, could be extrapolated into
an ideal dosage and spacing of the drug for malaria con-
trol. Implied is the standardization of current assays to
quantify ivermectin in blood from humans and animals
and also the development of sensitive assays to detect and
measure the drug in the midgut of fed mosquitoes.
Confirmation of lethal effects across a range of vector
bionomics
The lethal effects of ivermectin on all Anopheles species
tested so far is expected to extrapolate to exophagic and
exophilic vectors, such as Anopheles minimus and Anoph-
eles dirus in South-East Asia, Anopheles darlingi in South
America, and newly identified vectors [61]. However, this
must be confirmed by well-controlled studies, particularly
those assessing effects on wild populations.
The effects of current ivermectin MDA programmes on
malaria transmission
Only a few field trials examining the effects of ivermectin
on wild mosquito populations have occurred. They have
taken advantage of ongoing once-per-year anti-helminth
MDA programmes to assess collateral activity against mos-
quito survival or changes in the sporozoite rates [22].
Reductions in mosquito survival [21,23] and parasite trans-
mission from single MDA are expected to be temporary,
and the degree and duration of these reductions must be
thoroughly defined to eventually move to repeat MDA
trials (Definitive studies). Furthermore, effects must be
compared in diverse habitats containing different vectors
and malaria ecologies. In addition to direct anti-mosquito
effects, measures need to be made on expected changes in
Anopheles population structures (as determined by age-
grading), and third-order effects on entomological inocula-
tion rate (EIR), vectorial capacity, the molecular force of
infection, and the malaria reproductive rate (R0).
Modelling
Very few transmission models have included ivermectin
[20,23,35]. Current data suggests that the effect of a sin-
gle ivermectin dose administered to some 80% of a vil-
lage’s population could have a profound effect on the
age structure of the local Anopheles population, reducing
transmission for up to three weeks afterwards. Further
models fitted from empirical data will be essential to
help predict ideal ivermectin MDA dosing and fre-
quency, and the effects MDA might have on local mos-
quito population dynamics, Plasmodium transmission,
and human prevalence. Models will be important to pre-
dict changes of the above outcomes based on variables
such as weather, mosquito immigration, MDA compli-
ance and other concurrent vector control measures.
Anti-sporogony effects
A recent study [32] has demonstrated that sublethal
ivermectin concentrations affect P. falciparum transmis-
sion by inhibiting sporogony. These data suggest that
ivermectin MDA may reduce transmission for a longer
period than predicted based on anti-mosquito effects
alone, and also enhance ivermectin’s attractiveness to be
used in combination with anti-malarials to prevent re-
sidual transmission and inhibit the spread of anti-
malarial resistance. This study needs confirmation
using wild parasite isolates and with other Anopheles
and Plasmodium species.
Safety and formulation assessments
A single ivermectin MDA with coverage around 80%
disrupts malaria transmission in a community by chan-
ging the structure of the local mosquito population
[22,23]. The effect is longer than expected given the
current drug formulation´s short half-life. Modelling
[23,35] suggests that intermittent repeated administra-
tion would sustain control while minimizing mosquito
and helminth resistance development. However, an alter-
native, single-encounter, long-lasting formulation could
be less costly and more logistically feasible in MDA or
MSAT approaches, and likely superior in individualized
treatments meant to contain the spread of artemisinin-
resistant Plasmodium. While the current ivermectin
formulation should be tested over the short term,
longer-term research should focus on finding a formula-
tion capable of safely maintaining zero-order release for
a period long enough to have a lasting impact on the
malaria reproductive number (R0). Concurrent toxicity
studies must be done and possible interactions with
anti-malarials and other commonly used drugs assessed.
Emerging resistance
Ivermectin is of capital importance for the control of on-
chocerciasis, lymphatic filariasis and for the treatment of
some soil-transmitted helminths. Increasing the expos-
ure of parasites to the drug is likely to lead to resistance
in other parasites and jeopardize the success of control
programmes. Indeed, ivermectin resistance has been
documented in Sarcoptes scabiei in Australia and pos-
sibly in Onchocerca volvulus in Ghana [62]. Ongoing
surveillance must be established in communities where
ivermectin is introduced as a malaria control measure
and plausible methods to delay or reverse resistance ex-
plored. Combination therapy with a second anthelmin-
tic, such as a benzmidazole, might be effective. Likewise,
proper dosing and MDA spacing might delay ivermectin
resistance development in soil-transmitted helminths.
Ivermectin has a mechanism of action unrelated to
that of commonly used insecticides in malaria-endemic
regions. However, there must be early research on the
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possibility of resistance mechanisms in Anopheles, a bet-
ter understanding of the molecular targets of ivermectin
in the mosquito and possible metabolic detoxification
mechanisms that could foster cross-resistance.
Final comments
Available vector control tools are not effective enough to
achieve widespread malaria elimination or eradication,
and innovative approaches are needed. The use of iver-
mectin solves many challenges identified for future vector
control strategies. It is an effective and safe endectocide
that was approved for human use more than 30 years ago.
Recent studies suggest it might become an effective and
complementary strategy in malaria elimination and eradi-
cation efforts; however, intensive research will be needed
to make this a reality.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CJC and BDF wrote the first draft. All authors contributed and approved the
manuscript.
Acknowledgements
BDF was supported by grant 1R01AI094349-01A1 from the US National
Institutes of Health-National Institute of Allergy and Infectious Diseases.
The opinions or assertions contained herein are the private views of the
authors, and are not to be construed as official, or as reflecting true views of
the US Department of the Army or the Department of Defense.
We thank Juliane Chaccour for proofreading the manuscript.
Author details
1Internal Medicine Department, Clínica Universidad de Navarra, Av. Pio XII 36,
Pamplona 31008, Spain. 2Instituto de Salud Tropical, Universidad de Navarra,
Pamplona, Spain. 3Entomology Branch, Walter Reed Army Institute of
Research, Silver Spring, Maryland, USA. 4Barcelona Centre for International
Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Barcelona,
Spain. 5Centro de Investigação em Saúde de Manhiça (CISM), Maputo,
Mozambique. 6Department of Immunology and Infection, Faculty of
Infectious and Tropical Diseases, London School of Hygiene & Tropical
Medicine, London, UK. 7Department of Medical Microbiology, Radboud
University, Nijmegen Medical Centre, Nijmegen, The Netherlands.
8Arthropod-borne and Infectious Diseases Laboratory, Department of
Microbiology, Immunology and Pathology, Colorado State University,
1692 Campus Delivery, Fort Collins, Colorado 80523-1692, USA.
Received: 1 March 2013 Accepted: 1 May 2013
Published: 7 May 2013
References
1. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F,
Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD,
Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M: A research
agenda to underpin malaria eradication. PLoS Med 2011, 8:e1000406.
2. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy
PE: Malaria: progress, perils, and prospects for eradication. J Clin Invest
2008, 118:1266–1276.
3. Djogbenou L, Labbe P, Chandre F, Pasteur N, Weill M: Ace-1 duplication in
Anopheles gambiae: a challenge for malaria control. Malar J 2009, 8:70.
4. Ranson H, N’Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V: Pyrethroid
resistance in African anopheline mosquitoes: what are the implications
for malaria control? Trends Parasitol 2011, 27:91–98.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N,
Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455–467.
6. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein
L: Artemisinin resistance: current status and scenarios for containment.
Nat Rev Microbiol 2010, 8:272–280.
7. Roll Back Malaria Partnership: The Global Malaria Action Plan. Geneva; 2008.
http://www.rbm.who.int/gmap/gmap.pdf (accessed 28/04/2013).
8. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS,
Fullman N, Gosling RD, Feachem RG: The changing epidemiology of
malaria elimination: new strategies for new challenges. Lancet 2013. in
press.
9. The malERA Consultative Group on Vector Control: A research agenda for
malaria eradication: vector control. PLoS Med 2011, 8:e1000401.
10. Edi CV, Koudou BG, Jones CM, Weetman D, Ranson H: Multiple-insecticide
resistance in Anopheles gambiae mosquitoes, Southern Cote d’Ivoire.
Emerg Infect Dis 2012, 18:1508–1511.
11. Govella NJ, Ferguson H: Why use of interventions targeting outdoor biting
mosquitoes will be necessary to achieve malaria elimination. Front Physiol
2012, 3:199.
12. Kelly-Hope LA, McKenzie FE: The multiplicity of malaria transmission: a
review of entomological inoculation rate measurements and methods
across sub-Saharan Africa. Malar J 2009, 8:19.
13. Omura S: Ivermectin: 25 years and still going strong. Int J Antimicrob Agents
2008, 31:91–98.
14. Fox LM: Ivermectin: uses and impact 20 years on. Curr Opin Infect Dis 2006,
19:588–593.
15. Mectizan Donation Program: Annual Highlights; 2011. http://www.mectizan.
org/sites/www.mectizan.org/files/attachments/resources/Annual%
20Highlights%202011%20English.pdf (accessed 28/04/2013).
16. Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, Sylla M, Foy
BD: The effect of oral anthelmintics on the survivorship and re-feeding
frequency of anthropophilic mosquito disease vectors. Acta Trop 2010,
116:119–126.
17. Tesh RB, Guzman H: Mortality and infertility in adult mosquitoes after
the ingestion of blood containing ivermectin. AmJTrop Med Hyg 1990,
43:229–233.
18. Wilson ML: Avermectins in arthropod vector management - prospects
and pitfalls. Parasitol Today 1993, 9:83–87.
19. Chaccour C, Lines J, Whitty CJ: Effect of ivermectin on Anopheles gambiae
mosquitoes fed on humans: the potential of oral insecticides in malaria
control. J Infect Dis 2010, 202:113–116.
20. Foley DH, Bryan JH, Lawrence GW: The potential of ivermectin to control the
malaria vector Anopheles farauti. Trans R Soc Trop Med Hyg 2000, 94:625–628.
21. Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers
MP: Mass treatment with ivermectin for filariasis control in Papua New
Guinea: impact on mosquito survival. Med Vet Entomol 1999, 13:120–123.
22. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD: Ivermectin mass
drug administration to humans disrupts malaria parasite transmission in
Senegalese villages. AmJTrop Med Hyg 2011, 85:3–5.
23. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, Foy BD:
Mass drug administration of ivermectin in south-eastern Senegal reduces the
survivorship of wild-caught, blood fed malaria vectors. Malar J 2010, 9:365.
24. Pampiglione S, Majori G, Petrangeli G, Romi R: Avermectins, MK-933 and
MK-936, for mosquito control. Trans R Soc Trop Med Hyg 1985, 79:797–799.
25. Iakubovich V, Zakharova NF, Alekseev AN, Alekseev EA: Evaluation of the
action of ivermectin on blood-sucking mosquitoes. Med Parazitol (Mosk)
1989, 3:60–64.
26. Jones JW, Meisch MV, Meek CL, Bivin WS: Lethal effects of ivermectin on
Anopheles quadrimaculatus. J Am Mosq Control Assoc 1992, 8:278–280.
27. Gardner K, Meisch MV, Meek CL, Biven WS: Effects of ivermectin in canine
blood on Anopheles quadrimaculatus, Aedes albopictus and Culex
salinarius. J Am Mosq Control Assoc 1993, 9:400–402.
28. Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR: Toxicity of
bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann
Trop Med Parasitol 2009, 103:539–547.
29. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, Foy BD:
Comparative evaluation of systemic drugs for their effects against
Anopheles gambiae. Acta Trop 2012, 121:34–43.
30. Fritz ML, Walker ED, Miller JR: Lethal and sublethal effects of avermectin/
milbemycin parasiticides on the African malaria vector, Anopheles
arabiensis. J Med Entomol 2012, 49:326–331.
Chaccour et al. Malaria Journal 2013, 12:153 Page 7 of 8
http://www.malariajournal.com/content/12/1/153
31. Bastiaens G vGG, Hooghof J, Lindsay SW, Drakeley C, Churcher T, Verhave
JP, Kocken C, Sauerwein RW, Bousema T: Duration of the mosquitocidal
effect of ivermectin. MW Journal 2012, 3:1–5.
32. Kobylinski KC, Foy BD, Richardson JH: Ivermectin inhibits the sporogony of
Plasmodium falciparum in Anopheles gambiae. Malar J 2012, 11:381.
33. Garrett-Jones C, Shidrawi GR: Malaria vectorial capacity of a population of
Anopheles gambiae: an exercise in epidemiological entomology. Bull World
Health Organ 1969, 40:531–545.
34. Macdonald G: The analysis of equilibrium in malaria. Trop Dis Bull 1952,
49:813–829.
35. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M: Endectocides for
malaria control. Trends Parasitol 2011, 27:423–428.
36. Mackenzie CD, Geary TG, Gerlach JA: Possible pathogenic pathways in the
adverse clinical events seen following ivermectin administration to
onchocerciasis patients. Filaria J 2003, 2(1):S5.
37. Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS,
Kijlstra A: Ivermectin detection in serum of onchocerciasis patients:
relationship to adverse reactions. AmJTrop Med Hyg 1995, 52:94–97.
38. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq
M: Serious reactions after mass treatment of onchocerciasis with ivermectin
in an area endemic for Loa loa infection. Lancet 1997, 350:18–22.
39. Wanji S, Akotshi DO, Mutro MN, Tepage F, Ukety TO, Diggle PJ, Remme JH:
Validation of the rapid assessment procedure for loiasis (RAPLOA) in the
democratic republic of Congo. Parasit Vectors 2012, 5:25.
40. Duke BO, Pacque MC, Munoz B, Greene BM, Taylor HR: Viability of adult
Onchocerca volvulus after six 2-weekly doses of ivermectin. Bull World
Health Organ 1991, 69:163–168.
41. Awadzi K, Opoku NO, Addy ET, Quartey BT: The chemotherapy of
onchocerciasis. XIX: The clinical and laboratory tolerance of high dose
ivermectin. Trop Med Parasitol 1995, 46:131–137.
42. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM,
Sciberras DG, Hsieh JY, Lasseter KC: Safety, tolerability, and
pharmacokinetics of escalating high doses of ivermectin in healthy adult
subjects. J Clin Pharmacol 2002, 42:1122–1133.
43. Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq
M: Adverse systemic reactions to treatment of onchocerciasis with
ivermectin at normal and high doses given annually or three-monthly.
Trans R Soc Trop Med Hyg 2004, 98:496–504.
44. Merck & Co: Stromectrol. Package insert; 2009. http://www.accessdata.fda.
gov/drugsatfda_docs/label/2009/050742s026lbl.pdf (Accessed 28/04/2013).
45. Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR:
Pregnancy outcome after inadvertent ivermectin treatment during
community-based distribution. Lancet 1990, 336:1486–1489.
46. Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC: Absence of any
adverse effect of inadvertent ivermectin treatment during pregnancy.
Trans R Soc Trop Med Hyg 1993, 87:318.
47. Doumbo O, Soula G, Kodio B, Perrenoud M: Ivermectin and pregnancy in
mass treatment in Mali. Bull Soc Pathol Exot 1992, 85:247–251.
48. Gyapong JO, Chinbuah MA, Gyapong M: Inadvertent exposure of pregnant
women to ivermectin and albendazole during mass drug administration
for lymphatic filariasis. Trop Med Int Health 2003, 8:1093–1101.
49. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P: Efficacy of
ivermectin and albendazole alone and in combination for treatment of
soil-transmitted helminths in pregnancy and adverse events: a
randomized open label controlled intervention trial in Masindi district,
western Uganda. AmJTrop Med Hyg 2008, 79:856–863.
50. Brown KR: Changes in the use profile of Mectizan: 1987–1997. Ann Trop
Med Parasitol 1998, 92(Suppl 1):S61–64.
51. Ogbuokiri JE, Ozumba BC, Okonkwo PO: Ivermectin levels in human
breastmilk. Eur J Clin Pharmacol 1993, 45:389–390.
52. Gutman J, Emukah E, Okpala N, Okoro C, Obasi A, Miri ES, Richards FO Jr:
Effects of annual mass treatment with ivermectin for onchocerciasis on the
prevalence of intestinal helminths. AmJTrop Med Hyg 2010, 83:534–541.
53. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R,
Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: Moderate effect
of artemisinin-based combination therapy on transmission of
Plasmodium falciparum. J Infect Dis 2006, 193:1151–1159.
54. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R,
Pinder M, Walraven G, Targett GA: Reduction of malaria transmission to
Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med
2005, 2:e92.
55. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ,
Bousema T, Drakeley CJ, Ghani AC: The potential contribution of mass
treatment to the control of Plasmodium falciparum malaria. PLoS One
2011, 6:e20179.
56. von Seidlein L, Greenwood BM: Mass administrations of antimalarial
drugs. Trends Parasitol 2003, 19:452–460.
57. The malERA Consultative Group on Drugs: A research agenda for malaria
eradication: drugs. PLoS Med 2011, 8:e1000402.
58. Baird JK, Surjadjaja C: Consideration of ethics in primaquine therapy
against malaria transmission. Trends Parasitol 2011, 27:11–16.
59. Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet
F, Remoue F, Allan R, Fortes F, Carnevale P, Manguin S: Human antibody
response to Anopheles saliva for comparing the efficacy of three malaria
vector control methods in Balombo. Angola. PLoS One 2012, 7:e44189.
60. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I,
Chandramohan D, Theander T, Ronca R, Modiano D, Arca B, Drakeley C: IgG
responses to Anopheles gambiae salivary antigen gSG6 detect variation
in exposure to malaria vectors and disease risk. PLoS One 2012, 7:e40170.
61. Stevenson J, St Laurent B, Lobo NF, Cooke MK, Kahindi SC, Oriango RM,
Harbach RE, Cox J, Drakeley C: Novel vectors of malaria parasites in the
western highlands of Kenya. Emerg Infect Dis 2012, 18:1547–1549.
62. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO,
Prichard RK: Phenotypic evidence of emerging ivermectin resistance in
Onchocerca volvulus. PLoS Negl Trop Dis 2011, 5:e998.
doi:10.1186/1475-2875-12-153
Cite this article as: Chaccour et al.: Ivermectin to reduce malaria
transmission: a research agenda for a promising new tool for
elimination. Malaria Journal 2013 12:153.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chaccour et al. Malaria Journal 2013, 12:153 Page 8 of 8
http://www.malariajournal.com/content/12/1/153
